Spruce Biosciences, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$20M
D&A
$21K
Operating Income
$-37M
EBITDA
$-36M
Interest Expense
$90K
Tax Provision
$0
Net Income
$-39M
Operating Margin
-1143.4%
Net Margin
-1079.9%
Deferred Tax Assets
$177K
Deferred Tax Liabilities
$2K
DTA Valuation Allowance
$71M
Tax Credit Carryforwards
$2M
NOL Carryforwards
$45M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
—
Operating Lease Cost
$337K
Revenue YoY Variation
-100.0%
Income YoY Variation
35.0%